72. Remdesivir vs Standard Care in Patients with Moderate covid-19

BACKGROUND: Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Open Forum Infect Dis
Main Authors: Marty, Francisco M, Malhotra, Prashant, Gottlieb, Robert L, Tashima, Karen T, Galli, Massimo, Chai, Louis Yi Ann, SenGupta, Devi, Hyland, Robert H, Wang, Hongyuan, Zhong, Lijie, Cao, Huyen, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Brown, Michael, Goikoetxea, Ane Josune, Jain, Mamta, Hui, David Shu Cheong, Bernasconi, Enos, Spinner, Christoph
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Poster Abstracts
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777983/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.382
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker